Total revenue of $2.77 billion, down 40 basis points versus the prior year; earnings per share were $4.02 on a reported basis, down approximately 3% versus the prior year; and $3.96 on an adjusted basis, down 8% versus the prior year.
Adjusted earnings per share was $3.96 compared to $4.31 last year.
We have raised our outlook for the remainder of the year based on higher than anticipated COVID-19 volumes as well as our continued progress we expect to see in our base business.
Total revenue of $2.77 billion, down 40 basis points versus the prior year; earnings per share were $4.02 on a reported basis, down approximately 3% versus the prior year; and $3.96 on an adjusted basis, down 8% versus the prior year.
Reported earnings per share was $4.02 in the quarter compared to $4.14 a year ago.
Total revenue of $2.77 billion, down 40 basis points versus the prior year; earnings per share were $4.02 on a reported basis, down approximately 3% versus the prior year; and $3.96 on an adjusted basis, down 8% versus the prior year.
Adjusted earnings per share was $3.96 compared to $4.31 last year.
Well, we had a strong third quarter as COVID-19 molecular volumes increased throughout the summer.
In late summer, we experienced some softness in the base business across the country, but saw a rebound in September.
Importantly, our base business continued to improve sequentially in the third quarter, which speaks to the ongoing recovery.
For the third quarter, consolidated revenues were $2.77 billion, down 0.4% versus the prior year.
Revenue is expected to be between $10.45 billion and $10.6 billion, an increase of approximately 11% to 12% versus the prior year.
Reported earnings per share is expected to be in the range of $14.69 [Phonetic] and $15.09 and adjusted earnings per share to be in the range of $13.50 and $13.90.
Reported earnings per share is expected to be in the range of $14.69 [Phonetic] and $15.09 and adjusted earnings per share to be in the range of $13.50 and $13.90.
